Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.57 EUR | +1.06% | +4.00% | +1.72% |
Mar. 13 | Almirall Signs License Deal with Eloxx Pharmaceuticals for Skin Diseases Treatment | MT |
Feb. 19 | Global markets live: Apple, Nintendo, Super Micro Computer, Currys, ABB... |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- The company is in a robust financial situation considering its net cash and margin position.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- With an expected P/E ratio at 82.44 and 29.56 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+1.72% | 1.92B | B | ||
+34.00% | 704B | C+ | ||
+29.29% | 577B | B | ||
-7.75% | 348B | C+ | ||
+18.53% | 327B | B- | ||
+4.95% | 288B | C+ | ||
+13.79% | 234B | B+ | ||
+4.93% | 198B | B- | ||
-9.78% | 194B | A+ | ||
-4.89% | 147B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ALM Stock
- Ratings Almirall, S.A.